Phase II study of the oral hypoxia-inducible factor 2α (HIF-2 α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). Background: C ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results